

1 **Pregnancy Reduces Il33+ Hybrid Progenitor Accumulation in the Aged Mammary Gland**

2

3 Andrew Olander^{1*}, Cynthia M Ramirez^{2*}, Veronica Haro Acosta¹, Paloma Medina^{1,3,5}, Sara
4 Kaushik¹, Vanessa D Jonsson^{3,4}, Shaheen S Sikandar^{1,4,5#}

5

6 **Affiliations**

7 ¹Department of Molecular, Cell and Developmental Biology, University of California - Santa Cruz

8 ²Department of Applied Mathematics, University of California - Santa Cruz

9 ³Department of Biomolecular Engineering, University of California - Santa Cruz

10 ⁴Genomics Institute, University of California - Santa Cruz

11 ⁵Institute for the Biology of Stem Cells, University of California - Santa Cruz

12

13 *These authors contributed equally to the work

14 #Corresponding author: Shaheen Sikandar, ssikanda@ucsc.edu

15

16 **ABSTRACT:**

17 Aging increases breast cancer risk while an early first pregnancy reduces a woman's life-long risk.

18 Several studies have explored the effect of either aging or pregnancy on mammary epithelial cells

19 (MECs), but the combined effect of both remains unclear. Here, we interrogate the functional and

20 transcriptomic changes at single cell resolution in the mammary gland of aged nulliparous and

21 parous mice to discover that pregnancy normalizes age-related imbalances in lineage

22 composition, while also inducing a differentiated cell state. Importantly, we uncover a minority

23 population of *Il33*-expressing hybrid MECs with high cellular potency that accumulate in aged

24 nulliparous mice but is significantly reduced in aged parous mice. Functionally, IL33 treatment of

25 basal, but not luminal, epithelial cells from young mice phenocopies aged nulliparous MECs and

26 promotes formation of organoids with *Trp53* knockdown. Collectively, our study demonstrates that

27 pregnancy blocks the age-associated loss of lineage integrity in the basal layer through a
28 decrease in //33+ hybrid MECs, potentially contributing to pregnancy-induced breast cancer
29 protection.

30

31 INTRODUCTION

32 A woman's risk of breast cancer increases with age (median age at diagnosis = 62 years¹),
33 but an early first pregnancy (below the age of 30) significantly reduces lifetime risk²⁻⁸. Previous
34 studies that have examined changes shortly after pregnancy suggest that post-pregnancy
35 mammary epithelial cells (MECs) have a reduced stem cell capacity^{9,10} and increased expression
36 of differentiation markers¹¹. On the other hand, the studies that examined changes with aging in
37 nulliparous (no pregnancy) MECs have found an accumulation of dysfunctional luminal
38 progenitors¹², lineage infidelity¹³, and altered differentiation programs^{14,15}. Importantly, there is not
39 a clear understanding of how these processes combine and evolve with aging, i.e., how does
40 pregnancy alter the process of aging in mammary stem/progenitor cells?

41 Most of the previous studies focused on time points immediately post-pregnancy or 40
42 days post-involution (~3.3 human years), yet pregnancy-induced protection does not take effect
43 until almost 10 years post-birth^{4,16,17}. To address this gap in knowledge, we simulated conditions
44 that mimic an early first pregnancy (20-30 years in humans, 3-8 months in mice) and the post-
45 menopausal stage (>50 years in humans, ~18 months in mice). The long-term effect of pregnancy
46 on aging of MECs is important to determine because 75% breast cancer diagnoses occur over
47 the age of 50¹⁸, while most women in the United States have their first pregnancy between 20
48 and 33 years of age^{19,20}. Using this 18-month time point in conjunction with a 3-month control, we
49 interrogate the aging process of MECs with and without pregnancy while removing confounding
50 factors affecting human samples²¹. Our study not only delineates the combined effects of aging
51 and pregnancy, but also uncovers a previously unknown //33+ hybrid MEC population that
52 accumulates with age and is reduced in aged mice that have undergone pregnancy.

53

54 RESULTS

55 Pregnancy induces long lasting changes in cell fate decisions and reduces organoid 56 formation

57 To understand whether pregnancy alters the aging of the mammary gland, we compared
58 18-month-old parous mice (18m P) that have undergone multiple pregnancies between 3-8
59 months of age with 3-month-old nulliparous (3m NP) and 18-month-old nulliparous (18m NP) (**Fig.**
60 **1a**). H&E staining and whole mount imaging showed no major differences in ductal density,
61 morphology, or complexity of branching between 18m NP and 18m P (**Extended Data Fig. 1a,**
62 **b**).

63 The mammary gland is a bilayered tree-like structure composed of two main epithelial cell
64 lineages, luminal and basal cells²². Luminal cells can be further subdivided into two functionally
65 distinct cell types: hormone receptor (HR)-high and -low cells²³. To understand how these
66 populations evolve with aging and pregnancy, we performed flow cytometry analysis using
67 previously established markers of MEC lineages, basal (CD49F^{high}/EPCAM^{med-low}) and luminal
68 (CD49F^{med}/EPCAM^{high}) (**Extended Data Fig. 2**). We found that in 18m NP mice, there was a
69 significant increase in the basal population (increased basal:luminal ratio) as compared to 3m NP
70 mice (**Fig. 1b, d**), consistent with previous studies²⁴. However, 18m P mice showed a
71 basal:luminal ratio lower than 18m NP but still higher than 3m NP mice, suggesting that pregnancy
72 partially normalizes the aged-induced expansion of basal cells (**Fig. 1b, d**).

73 Within the luminal compartment, our analysis showed a minor but non-significant increase
74 in HR-low luminal cells (CD14+/CD33-) and a significant decrease in HR-high luminal cells (CD14-
75 /CD133+) in the 18m NP mice (**Fig. 1c, e**), consistent with previous studies in 13-14 month mice²³.
76 However, in contrast to the normalization of basal:luminal ratio in 18m P mice, we found a further
77 increase in HR-low and a decrease in HR-high luminal cells in these mice (**Fig 1c, e**). Thus, our
78 data suggests that while the age-induced expansion of basal cells is normalized by pregnancy,

79 the luminal cells retain a residual involution program, with an increased proportion of CD14+ HR-
80 low luminal cells.

81 To understand whether there are functional differences in luminal and basal cells between
82 the 3m NP, 18m NP and 18m P mice, we performed *in vitro* organoid assays. In contrast to
83 previous studies that have shown an age-induced increase in organoid formation²⁴, we found that
84 3m and 18m NP MECs had similar capacity to form organoids (**Fig. 1, f-i**). However, both luminal
85 and basal cells from 18m P mice had a significantly decreased capacity of organoid formation as
86 compared to 18m NP mice (**Fig. 1f-i**). These findings suggest that MECs from the aged parous
87 glands are diminished in clonogenicity, supporting the hypothesis that pregnancy reduces
88 regenerative potential.

89

90 **Pregnancy promotes a differentiated cell state but also reverses aged-associated** 91 **transcriptional programs**

92 To determine transcriptomic changes in response to aging and pregnancy, we sorted
93 luminal and basal cells and performed bulk RNA sequencing from 3m NP, 18m NP, and 18m P
94 mice. Principal component analysis (PCA) of gene expression values showed that luminal and
95 basal samples formed two distinct clusters (**Fig. 2a**), as expected. Moreover, gene expression for
96 established lineage markers showed that sorting was specific for basal and luminal cells, with
97 enrichment of *Krt14*, *Krt5*, and *Acta2* in the basal cells and *Krt8*, and *Krt18* in luminal cells (**Fig.**
98 **2b**).

99 To understand the long-term effects of pregnancy on gene expression in MECs, we
100 performed differential gene expression analysis between 18m NP and 18m P for basal and
101 luminal cells. Although luminal cells undergo significant functional and transcriptomic changes
102 throughout pregnancy²⁵, we found only 45 differentially expressed genes (DEGs) at p-adj of \leq
103 0.1 that are persistently altered in luminal cells (**Data Table 1**). Interestingly, we found 74 DEGs
104 in basal cells at the same p-adj threshold (**Data Table 2**). Previous studies suggest that parity has

105 the most pronounced impact on the transcriptome of luminal cells²⁵, but our data suggest that
106 basal cells also retain a robust transcriptional memory of pregnancy that persists with age. Basal
107 cells from 18m P mice displayed consistent upregulation of genes associated with differentiation
108 towards a mesenchymal lineage and contractile functions, such as *Myod1*, *Fmod*, and *Vim* (**Fig.**
109 **2c**). Moreover, 18m P basal cells had increased expression of milk-protein genes, such as
110 *Csn1s1* and *Csn2*, suggesting that basal cells upregulate pathways of milk-production during
111 pregnancy or give rise to milk producing cells²⁶, or vice versa²⁷. We also detected a modest down
112 regulation of genes associated with stem/progenitor cells (*Tspan8* and *Bcl11b*)^{28,29} and growth
113 factor receptors (*Erb3* and *Egr2*). Likewise, luminal cells from 18m P mice had higher expression
114 of genes involved in alveolar differentiation (*Csn1s1*, *Csn2*, *Car2*, and *Apobr*) and down regulation
115 of genes involved in stem/progenitor function (*Runx3* and *Bst1*, **Fig. 2d**). Taken together, these
116 results suggest that pregnancy establishes long-term transcriptomic changes that reflect
117 increased differentiation not only in luminal cells but also in basal cells. Interestingly, by comparing
118 the gene expression patterns between 3m NP, 18m NP and 18m P mice we found that expression
119 of *Tspan8*, that marks hormone-responsive stem cells²⁸ and growth factor receptors (*Erb3* and
120 *Egr2*) increases with aging in basal cells but is reduced in 18m P mice (**Fig. 2c**). Similar patterns
121 were observed for luminal cells in stem/progenitor genes (*Runx3* and *Bst1*), the RANKL decoy
122 receptor, *Tnfrsf11b*, and the *Wnt* inhibitor, *Nkd2*, among others (**Fig. 2d**, see Data tables 1-4).

123 To identify specific pathways that are altered by pregnancy and persist with age, we
124 performed gene ontology analysis on basal or luminal cells in 18m P and 18m NP mice. We found
125 significant enrichment of genes involved in cytoskeletal remodeling, extracellular matrix, and
126 contractile functions (**Fig. 2e**). Similarly, 18m P luminal cells showed enrichment of pathways
127 involved in regulation of peptide metabolism, antimicrobial immune responses, and collagen
128 structure (**Fig. 2f**), which have been proposed to play key roles during alveologenesis,
129 involution³⁰, and immune development of offspring^{31,32}. These data suggest that pregnancy

130 normalizes age-induced transcriptional changes in luminal and basal epithelial cells, while also
131 inducing a differentiated state.

132

133 **Single-cell RNA-sequencing identifies a minority population of hybrid MECs in aged** 134 **nulliparous mice**

135 Recent studies have demonstrated that minority populations of stem/progenitor cells
136 evolve with age and are likely precursors of tumor initiation^{24,33}. To investigate the cellular
137 heterogeneity and aging-associated transcriptional changes that are altered with pregnancy at
138 single-cell resolution, we performed single-cell RNA-sequencing (scRNA-seq) on mammary
139 glands from 18m NP and 18m P mice. To increase the power of our analysis, we integrated single
140 cell transcriptomes from the Tabula Muris³⁴ 18m mammary gland dataset (see methods). After
141 filtering cells with low-expressing genes, high mitochondrial counts, and doublets (see methods),
142 we identified epithelial cells (basal, HR-high luminal, HR-low luminal), immune cells (B cells, T
143 cells, macrophages), endothelial cells, and fibroblasts using the expression of well-established
144 marker genes (**Fig. 3a, Extended Data Fig. 3a**). Intriguingly, we identified a minority population
145 of cells co-expressing basal and luminal markers (hybrid) (**Fig. 3c**), that are present in 18m NP
146 mice (~90% of cell cluster) but are significantly reduced in 18m P mice (~10% of cell cluster) (**Fig.**
147 **3b**). Moreover, we found no differences in the proportion of B cells, T cells, macrophages,
148 endothelial cells, and HR-low luminal cells between 18m P and 18m NP (**Fig. 3b**). However, 18m
149 P had a lower proportion of basal cells and HR-high luminal cells (**Fig. 3b**), consistent with our
150 flow cytometry analyses (**Fig. 1b-e**). Moreover, we did not find differences in cell cycle between
151 18m NP and 18m P mice (**Extended Data Fig. 3b**).

152 To investigate the unknown hybrid population further, we calculated basal cell and luminal
153 cell gene signature enrichment scores for all cells based on previously published transcriptomic
154 analyses of adult MECs³⁵. We found that the hybrid MEC population lies between the luminal and
155 basal populations, implying that hybrid MECs display a mixed gene signature of both basal and

156 luminal lineages (**Fig. 3d**). Pseudotime inference using PAGA³⁶ and Slingshot³⁷ also predicted
157 the hybrid MECs lineage trajectory between basal and luminal populations (**Fig. 3e, Extended**
158 **Data Fig. 4a, b**).

159 To understand whether these hybrid MECs represent an immature cell type, we applied
160 CytoTRACE2³⁸, to agnostically predict cellular potency. Intriguingly, we found that 33% hybrid
161 MECs are predicted to be multipotent, while majority of basal and luminal cells were predicted to
162 be oligopotent and differentiated, respectively. Moreover, the average cellular potency of hybrid
163 MECs was between basal and luminal cells (**Fig. 3f, Extended Data Fig. 4c**). Intriguingly, the
164 hybrid MECs are also enriched in expression of *Krt6a* (**Extended Data Fig. 5a**), which has been
165 previously identified as a marker of bipotent luminal progenitor cells in the mammary gland³⁹.
166 KRT6a+ cells are normally found only in the luminal layer and do not express the basal marker
167 *Krt14*. However, a previous report showed that a population of KRT14+/KRT6a+ cells expands
168 during early stages of pregnancy⁴⁰. Analysis of the Pal et al. (2017) scRNA-seq dataset containing
169 all mammary gland developmental stages showed that *Krt6a* expression peaks during early
170 pubertal development, particularly within terminal end buds (TEBs)⁴¹ (**Extended Data Fig. 5b, c**).
171 Taken together, these data suggest that aging coincides with aberrant activation of *Krt6a*
172 expression likely conferring a cell state similar to TEBs, but this is diminished by pregnancy.

173

174 **Hybrid KRT6a+ cells are present in the basal epithelium of aged nulliparous mice but not**
175 **aged parous mice.**

176 To expand our analysis from mRNA to protein, we performed immunofluorescence
177 staining on 3m NP, 18m NP, and 18m P mammary glands for KRT6a, together with KRT8 (luminal
178 marker) and KRT5 (basal marker). We found a greater than 6-fold increase in the percentage of
179 KRT6a+ cells in the 18m NP (6.51%) mice relative to 3m NP (~1.05%) (**Fig. 3g, h**), suggesting
180 that these hybrid MECs accumulate over the course of aging. However, 18m P mice had a small
181 percentage of KRT6a+ cells (<1%), less than the 3m NP (**Fig. 3g, h**), consistent with our single-

182 cell analysis. Moreover, we found an increased percentage of KRT5+ basal cells and decreased
183 percentage of KRT8+ luminal cells in 18m NP mice (**Extended Data Fig. 5d**) consistent with our
184 flow cytometry data (**Fig. 1b, d**), but 18m P cells were more similar to 3m NP cells.

185 To further understand the localization of the KRT6a+ cells, we quantified the percentage
186 of KRT6a+ cells in the luminal and basal layer (i.e., KRT6a+/KRT8+ or KRT6a+/KRT5+). We
187 found that 95% of KRT6a+ cells in 3m NP glands were positive for KRT8 and resided in the
188 luminal layer (**Fig. 3i**), consistent with previous studies³⁹. In contrast, over 50% of KRT6a+ cells
189 in the 18m NP gland were positive for KRT5 and localized to the basal layer. Interestingly, in the
190 18m P mice, the localization of the KRT6a+ cells was closer to 3m NP mice (~10%, **Fig. 3i**). This
191 suggests that the KRT6a+ hybrid MECs that accumulate with age are likely due to the loss of
192 lineage integrity of basal cells, but this integrity is maintained in mice that have undergone
193 pregnancy.

194

195 **IL33 treatment of young basal cells phenocopies aged nulliparous mammary glands**

196 In addition to *Krt6a*, the hybrid MEC population identified in 18m NP mice was uniquely
197 enriched in the expression of *Interleukin 33 (Il33)* (**Fig. 3c, Extended Data Fig. 6a**), also known
198 as alarmin. IL33 has been previously implicated in activating pro-tumorigenic signaling
199 pathways⁴²⁻⁴⁴, cancer stem cell maintenance⁴⁵, and establishing an immunosuppressive
200 microenvironment⁴⁶, but its role in the normal mammary gland is unknown. Analysis of the Pal et
201 al. (2017) scRNA-seq dataset showed that *Il33* is also highly expressed in the TEBs during
202 puberty, (**Extended Data Fig. 6b, c**), similar to *Krt6a* (**Extended Data Fig. 5b, c**) suggesting that
203 aging likely upregulates an early developmental program in basal cells.

204 To determine whether IL33 treatment affects primary MECs *in vitro*, we cultured basal
205 (CD49^{hi}/EPCAM^{lo/med}) or luminal (CD49^{lo}/EPCAM^{hi}) cells from 3m NP mice with recombinant
206 IL33. Treatment of basal and luminal cells with IL33 resulted in an increased number of basal-
207 derived organoids (**Fig. 4a**) but no increase in organoids derived from luminal cells (**Extended**

208 **Data Fig. 6d**). Interestingly, IL33 treatment of basal organoids for 2 weeks inhibited spontaneous
209 *in vitro* luminal cell differentiation, resulting in a ~2-fold increase in the proportion of basal cells
210 (**Fig. 4b**). Moreover, IF staining and 3D imaging demonstrated an increase in the percentage of
211 KRT6a and KRT5 upon treatment with IL33 (**Fig. 4c, Extended Data Fig. 6e**), but no significant
212 change in KRT8+ luminal cells (**Extended Data Fig. 6f, g**). These results suggest IL33 treatment
213 of 3m NP basal cells phenocopies the increased proportion of basal cells and accumulation of
214 KRT6a+ hybrid MECs observed in aged nulliparous mice (**Fig. 3i**).

215 To test whether IL33 treatment increases clonogenicity in cells with tumor-promoting
216 mutations, we infected 3m NP basal and luminal cells with lentiviral shRNA targeting *Trp53*⁴⁷ and
217 exposed them to IL33. Consistent with our results in normal epithelial cells (**Fig. 4a, Extended**
218 **Data Fig. 6d**), we found that *Trp53* knockdown resulted in increased clonogenicity of basal cells
219 when treated with IL33 but not luminal cells (**Fig. 4d**). Thus, our data suggest that the age-induced
220 increase in *IL33*+ hybrid MECs likely confers a survival advantage as cells acquire oncogenic
221 mutations.

222

223 DISCUSSION

224 Our study resolves the complex relationship between aging and pregnancy in the
225 mammary gland, such as basal-cell bias and differentiation. We report that pregnancy not only
226 normalizes the age-induced expansion of basal cells but also concurrently reduces the capacity
227 of basal cells to form organoids. In contrast, luminal cells in aged parous mice retain an involution
228 specific signature, which potentially makes them more susceptible to immune surveillance⁴⁸⁻⁵¹.

229 Hybrid MECs expressing luminal and basal genes have been identified previously and are
230 associated with a less-differentiated phenotype, higher plasticity, and are capable of tumor
231 initiation⁵²⁻⁵⁵ but precise molecular signatures of these cells are not yet defined. Our work
232 identifies a previously unknown *IL33*+ hybrid MEC population that accumulates with age in the
233 basal layer. Majority of studies on breast tumor initiation implicate luminal cells as the cell of

234 origin⁵⁶, that lose lineage integrity to express basal markers during tumor initiation and also with
235 aging^{12–15}. However, our study suggests that basal cells can acquire hybrid features with aging
236 by turning on pathways active in luminal cells during early pubertal development. In support of
237 this model, studies have shown that basal cells can acquire hybrid phenotypes upon
238 transformation⁵⁷ and form luminal-like tumors^{52,54}, which are the predominant subtypes found in
239 postmenopausal breast cancers⁵⁸. Future work will determine the precise contribution of basal
240 cells to tumor initiation with aging.

241 The postnatal mammary gland development and maintenance is largely driven by lineage
242 committed progenitor cells that expand during pregnancy to form the milk-producing cells^{59–61}.
243 Studies have also shown that there are rare bipotent mammary stem cells in the basal layer that
244 can expand with pregnancy and contribute to the alveolar lineage^{61,62}. We speculate that during
245 pregnancy some basal cells either turn on an alveolar gene expression program or directly
246 contribute to the alveolar lineage, leading to the normalization of the basal:luminal ratio and a
247 decrease in the hybrid MEC population in aged parous mice.

248 IL33 has been extensively studied in inflammation and immune cell responses⁶³ but its
249 role in epithelial cell plasticity is unknown. Our results show that IL33 increases organoid
250 formation capacity and induces a KRT6a+ hybrid state in basal cells. Recent work has uncovered
251 a role for IL33 in pancreatic cancer where *Il33* expression is induced post-injury and cooperates
252 with mutant *Kras* to promote neoplastic transformation⁶⁴. Notably, when cells acquire hybrid
253 signatures due to expression of *Pik3ca*^{H1047R} in luminal cells, they dramatically increase the
254 expression of *Il33*⁵⁴. Moreover, studies have demonstrated a cell-intrinsic role of IL33 in B-cell
255 development⁶⁵, repair during skin injury⁶⁶, and promoting inflammation in chronic pancreatitis⁶⁷.
256 These studies, combined with our data, suggest that *Il33* expression promotes a cell-state that is
257 proliferative and plastic, allowing for injury repair or reprogramming during transformation. Future
258 studies will determine the cell intrinsic role of *Il33* during mammary gland development, in
259 establishing a hybrid cell state, and tumorigenesis.

260 **METHODS**

261 **Mice**

262 Wild-type C57BL/6 mice (young), retired breeders and aged matched mice when appropriate
263 were purchased from Charles River Laboratories and The Jackson Laboratory. Simultaneously
264 an aging colony was maintained in house. The mice were recorded for estrous and 18m mice
265 were found to be non-cycling. All mice used for this study were maintained at the UCSC Animal
266 Facility/Vivarium in accordance with the guidelines of the Institutional Animal Care and Use
267 Committee (Protocol #Sikas2311dn).

268

269 **H&E staining and quantification**

270 H&E staining was performed as previously described⁶⁸. Briefly, mammary glands were dissected
271 from parous and nulliparous mice, fixed in 4% PFA and paraffin embedded for histology. Sections
272 underwent a standard staining protocol, with five-minute incubation in 100% xylene and ethanol
273 (100%, 70%) followed by DI water for deparaffinization. Sections were stained with Hematoxylin
274 for 30 seconds, then bluing solution (NH₃OH + MilliQ H₂O, 2 mins) and Eosin for 1min followed
275 by dehydration and mounting (Permount). Visualization of mammary gland ducts was performed
276 using the Leica Widefield microscope, and ductal quantification was conducted using Fiji.

277

278 **Mammary gland whole mounts and branching analysis**

279 Inguinal mammary glands were removed, adhered to a Superfrost Plus Microscope slide
280 (Fisherbrand Cat. No. 1255015) and incubated in Carnoy's Fixative overnight at room
281 temperature. Mammary glands were then incubated in 70% ethanol, 50% ethanol, then DI water
282 for 15 minutes each. Fixed mammary glands were stained overnight with Carmine Alum at room
283 temperature, then dehydrated in 15-minute incubations in increasing ethanol grades, followed by
284 dehydration in xylene and mounted in Permount.

285 Images of the entire mammary gland wholemount for both parous and nulliparous samples were
286 imported as a TIFF file onto the Fiji/ImageJ software, where a three-by-three tiled ROI was chosen
287 from a consistent distance from the lymph node. The ROI was processed to remove background
288 noise. The image was skeletonized, and the branches dilated to improve clarity. A Sholl analysis
289 (neuroanatomy) plugin was used on the skeletonized image, and a vertical radius from the side
290 of the image was set as a consistent measurement throughout all samples to account for
291 decreased branching normally seen at the edges of an image. After setting the starting radius as
292 zero microns and selecting the best-fitting Sholl methods, the Sholl analysis program was run.
293 This generated a “Sholl Log Plot,” which indicated branching intersections over an area, as well
294 as a “Sholl Regression Coefficient (k)”, which described branching complexity. A k value closer
295 to zero indicated a higher branching complexity. A “Sholl Mask (heat map)” was also generated
296 to visually depict regions of higher branching complexity, where the red areas indicated maximal
297 branching.

298

299 **Immunofluorescent staining of mammary gland paraffin sections**

300 Mammary glands were fixed in 4% paraformaldehyde (PFA) in PBS and embedded in paraffin for
301 immunostaining. 5µm sections were deparaffinized, dehydrated, and autoclaved for 15 min in
302 Tris-EDTA buffer [10mM Tris 1mM EDTA (pH 9.0)] for antigen retrieval. Tissue sections were
303 incubated overnight at 4°C with primary antibodies diluted in tris-buffered saline (TBS) + 5%
304 bovine serum albumin (BSA) (antibodies are listed in table 5). Samples were subsequently
305 washed (2X) with TBS + 0.05% Tween for 10 min and were incubated with donkey anti-rat Alexa
306 Flour 647 (1:400), donkey anti-chicken Alexa Flour 488 (1:400), donkey anti-rabbit Alexa Flour
307 594 (1:400) conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) in TBS +
308 5% BSA 0.1% Tween for 1 hour at room temperature (RT). Samples were subsequently washed
309 (3X) with TBS + 0.1% Tween and were incubated with DAPI in TBS + 5% BSA + 0.1% Tween
310 (1:10,000) for 10 min. All the immunofluorescence sections and cells were mounted in

311 Fluoromount-G (Genesee). Images were acquired by a Solamere Spinning Disk Confocal
312 microscope. Images were processed using Fiji.

313

314 **Immunofluorescent staining of primary MEC organoids**

315 Organoids were collected at day 12-14 in culture and recovered from the growth factor-reduced
316 Matrigel by incubating with Cell Recovery Solution (Corning) for 1 hour on ice with gentle shaking.
317 5mL collection tubes and pipette tips were precoated in PBS + 5% BSA. Organoids were washed
318 with cold PBS (2X) before being fixed with 4% PFA in PBS for 45 min on ice. Fixed organoids
319 were then washed in PBS (1X) and incubated with 0.2% glycine in PBS for 20 min at room
320 temperature. After a final wash, fixed organoids were resuspended in 0.05% sodium azide in PBS
321 and stored at 4°C.

322 Organoids were permeabilized in cold 100% methanol for 10 minutes on ice, washed PBS (1X),
323 and incubated in blocking buffer (0.1% BSA, 0.3% Triton-X, 5% normal donkey serum) for 3h at
324 room temperature with light shaking followed by overnight incubation with primary antibodies in
325 blocking buffer at 4°C with light shaking. The next day they were washed (3X) in PBS + 0.3%
326 Triton-X and incubated overnight with secondary antibodies in a blocking buffer at 4°C with light
327 shaking in the dark. Organoids were again washed (3X) in PBS + 0.3% Triton-X and incubated
328 with DAPI for 10 min at room temperature. After a final round of washes (3X), organoids were
329 transferred to μ -Slide 8 Well Glass Bottom slide (Ibidi) pre-coated in poly-L-lysine (Sigma-Aldrich)
330 and imaged on a Solamere Spinning Disk Confocal microscope. Images were processed using
331 Fiji.

332

333 **Organoid assays**

334 Primary MECs were sorted into complete organoid media as previous described^{68,69} (Advanced
335 DMEM F/12, 10% FBS, 1% PSA, 50ng/mL EGF, 100ng/mL Noggin, 250ng/mL R-Spondin-1, 1X
336 N2, 1X B27, 1X GlutaMAX, 10mM HEPES) supplemented with Y-27632 (10uM). 1,000 cells were

337 plated in 96-well ultra-low attachment plates seeded with a 50uL mixture of growth factor-reduced
338 Matrigel and irradiated L-Wnt3a-secreting-3T3 feeder cells (11,000 feeder cells per 50uL growth
339 factor-reduced Matrigel). Organoids were cultured at 37C, 5% CO2 with added humidity. On day
340 4, Y-27632 supplemented media was removed and replaced with complete organoid media.
341 Fresh media was added every other day thereafter. Basal and luminal organoids were imaged at
342 day 6 and 10 in culture, respectively, on a Zeiss Live Cell microscope and analyzed on Biodoc.AI
343 to collect data on organoid count and average size. For IL33 treatment experiments, organoids
344 were cultured as described above with the addition of IL33 (0ng/mL, 5ng/mL, 10ng/mL).

345

346 **Mammary gland digestion and processing**

347 L2-5 and R2-5 mammary glands were harvested, minced, and chemically digested overnight in
348 Advanced DMEM F/12 with 1% PSA, gentle collagenase/hyaluronidase, and DNase I at 37C, 5%
349 CO2, and added humidity as previously described⁷⁰. Briefly, partially digested glands were then
350 mechanically digested by pipetting with a serological pipette until no tissue pieces were visible.
351 Digested glands were washed with staining buffer (Hank's Balanced Salt Solution, 2% Bovine
352 Calf Serum, 1% PSA) and centrifuged (1500RPM) at 4C for 5 minutes. Red blood cells were lysed
353 with 5mL of ACK Lysis buffer for 5 minutes, and cells were washed with 15mL of staining buffer.
354 Cells were treated with 0.25% Trypsin with EDTA and gently pipetted continuously for 2-3 minutes
355 to digest the basement membrane. Cells were then treated with DNase I and Dispase and
356 pipetted continuously for 2-3 minutes to prevent clumping. The single-cell suspension was then
357 filtered through a 40um mesh strainer and pelleted via centrifugation (1500RPM, 4C, 5 minutes).
358 Cells were then resuspended in staining buffer and transferred to FACS tubes for staining.

359

360 **Fluorescence-activated cell sorting (FACS)**

361 Cells were stained with antibodies listed in Supplemental Table 5 for 15 minutes at room
362 temperature, as previously described^{68,69}. Stained cells were then washed with a staining buffer,

363 resuspended with DAPI (1:10,000), filtered, and analyzed on a BD Biosciences FACSAria cell
364 sorter. See Extended Data Fig. 2 for FACS gating strategies. Data were analyzed using FlowJo
365 software (10.10.0).

366

367 **Lentiviral Infection**

368 For *Trp53* knockdown experiments, pSicoR-GFP-sh*Trp53* was a gift from Tyler Jacks (Addgene
369 plasmid #12090; <http://n2t.net/addgene:12090> ; RRID:Addgene_12090). Viruses were produced
370 in 293T cells using the second-generation lentiviral system and transfection using Lipofectamine
371 2000 (Life Technologies) as previously described⁷⁰. Supernatants were collected at 48 hours,
372 filtered with a 0.45µm filter, and precipitated with lentivirus precipitation solution (Alstem LLC) per
373 the manufacturer's instructions. Viral titers were determined by flow cytometry analyses of 293T
374 cells infected with serial dilutions of concentrated virus.

375

376 **Single-cell RNA-seq cell preparation and sequencing**

377 Libraries were generated using the 10x Genomics Chromium Next GEM Single Cell 5' Reagent
378 Kits v2 (Dual Index) (cat#1000264) following the manufacturer's protocol. Single-cell suspensions
379 were prepared from mammary glands as described above and encapsulated using the Chromium
380 Controller to generate Gel Beads-in-Emulsion (GEMs), allowing for barcoding of individual cells.
381 Post-GEM generation, reverse transcription (GEM-RT) was performed within each GEM, followed
382 by cleanup and cDNA amplification. The cDNA underwent fragmentation, end repair, and A-
383 tailing. Dual index adapters were ligated to the cDNA fragments, which were then amplified using
384 PCR. The libraries were quantified using a Qubit Flex Fluorometer (Invitrogen Q33327) and their
385 size distribution was assessed using an Agilent TapeStation 4200. Sequencing libraries were
386 constructed to target 200 million paired-end reads (400 million total) to achieve a coverage of
387 20,000 reads per cell from a targeted capture of 10,000 cells. Sequencing was performed on an
388 Illumina NovaSeq 6000 following the manufacturer's recommendations.

389 **Single-cell data pre-processing and quality control**

390 Sequencing data was processed using the 10x Genomics Cell Ranger pipeline. Reads were
391 aligned to the mouse reference genome (mm10). We performed quality control for downstream
392 analysis, removing (1) genes that were detected in less than 3 cells, (2) cells with less than 200
393 genes, (3) cells with gene counts < 600 or > 8,000, (4) cells with total counts of UMIs per cell <
394 2,000 or > 12,000, and (5) cells with mitochondrial gene ratio > 1.5%. The mitochondrial gene
395 ratio is defined as the percentage of UMIs mapped to mitochondrial genes compared to non-
396 mitochondrial genes within each cell. Doublets were identified using Scrublet⁷³, resulting in the
397 removal of 588 cells. Data preprocessing and analysis steps below were implemented using the
398 Scanpy framework version 1.19⁷¹.

399

400 **Single cell data integration, dimension reduction, and cell type annotation**

401 We combined our single cell data set with an 18 month nulliparous pre-processed single cell data
402 set from Tabula Muris Senis³⁴. The UMI counts for each cell were normalized using a target sum
403 of 1e4, and log transformed, with an added pseudocount of 1. This resulted in a combined dataset
404 of 10,001 cells and 13,892 genes. Principal component analysis (PCA) was conducted to produce
405 a reduced dataset that was used as input to correct for technical variation due to samples using
406 Harmony, version 0.0.4⁷². Neighborhood graphs were calculated on batch corrected reduced
407 data and used to conduct Leiden⁷³ unsupervised clustering, with a resolution of 0.09, resulting in
408 the identification of nine distinct clusters. These clusters were manually annotated using well-
409 established marker genes. Data was visualized using Uniform Manifold Approximation and
410 Projection (UMAP, version 0.5.2)⁷⁴.

411

412 **Cell-cycle analysis, basal and luminal gene scoring**

413 Cell cycle enrichment analysis was conducted using the Regev lab cell cycle gene list⁷⁵ to classify
414 each cell into its corresponding cell cycle phase. To classify epithelial cells, we used previously

415 published marker genes identified for Basal, HR-high Luminal, and HR-low Luminal cells from
416 transcriptomic analyses of adult mammary epithelial cells (MECs)³⁵. Enrichment scores for these
417 marker genes were calculated for each of the four epithelial cell types (Basal epithelial, HR-high
418 Luminal, HR-low Luminal, and Hybrid MECs). Cell cycle and epithelial cell type classifications
419 were conducted using the 'sc.tl.score_genes' function from the Scanpy library⁷¹.

420

421 **Pseudotime inference and cellular potency prediction**

422 Pseudotime analysis was performed on the epithelial cell types (basal, HR-low, HR-high, and
423 hybrid). Partition-based graph abstraction (PAGA, version 1.2)³⁶ analysis was performed using
424 Scanpy (version 1.9.6). The diffusion map was computed using the basal cell type as the root cell.
425 To ensure robustness, pseudotime trajectory was also inferred using Python's implementation of
426 Slingshot (pyslingshot, version 0.1.3)³⁷, with basal cells as the start node. Slingshot pseudotime
427 ordering scores were scaled between 0 and 1 for comparison with PAGA results. To characterize
428 cellular potency, we used Python's implementation of CytoTRACE 2 (version 1.0.0)³⁸. Figures
429 were generated using a combination of Scanpy⁷¹, Seaborn⁷⁶, and matplotlib python packages⁷⁷.
430 To assess the statistical significance of the differences in pseudotime between epithelial cell
431 types, we performed pairwise comparison using the Wilcoxon Rank Sum Test using Benjamini-
432 Hochberg correction method to adjust the p-values and control the false discovery rate. For this
433 analysis we used 'scipy.stats.mannwhitneyu' function⁷⁸ for the Wilcoxon Rank Sum Test and
434 'multipletests' from the 'statsmodels.stats.multitest' library for Benjamini-Hochberg testing
435 correction⁷⁹.

436

437 **Library Construction, Quality Control and Bulk RNA Sequencing**

438 Bulk RNA sequencing was performed by Novogene on sorted basal (CD49^{hi}/EPCAM^{low-med}) and
439 luminal (CD49^{low}/EPCAM^{hi}) populations from 3m NP, 18m NP and 18m P mice (n=3 mice/group).
440 RNA was isolated according to manufacturer's instructions (Qiagen RNEasy Plus Micro Kit, Cat.

441 No. 74034). Messenger RNA was purified from total RNA using poly-T oligo-attached magnetic
442 beads. After fragmentation, the first strand cDNA was synthesized using random hexamer
443 primers, followed by the second strand cDNA synthesis using either dUTP for directional library
444 or dTTP for non-directional library⁸⁰. For the non-directional library, it was ready after end repair,
445 A-tailing, adapter ligation, size selection, amplification, and purification. For the directional library,
446 it was ready after end repair, A-tailing, adapter ligation, size selection, USER enzyme digestion,
447 amplification, and purification. The library was checked with Qubit and real-time PCR for
448 quantification and bioanalyzer for size distribution detection. Quantified libraries will be pooled
449 and sequenced on Illumina platforms, according to effective library concentration and data
450 amount.

451

452 **Data Quality Control**

453 Raw data (raw reads) of fastq format were processed through fastp software. In this step, clean
454 data (clean reads) were obtained by removing reads containing adapter, reads containing poly-N
455 and low quality reads from raw data. Q20, Q30 and GC content were calculated. All the
456 downstream analyses were based on the clean data with high quality.

457

458 **Reads mapping to the reference genome**

459 Reference genome (GRCm39/mm39) and gene model annotation files were downloaded from
460 genome website directly. Index of the reference genome was built using Hisat2 v2.0.5 and paired-
461 end clean 1 reads were aligned to the reference genome using Hisat2 v2.0.5. We selected
462 Hisat2⁸¹ as the mapping tool for that Hisat2 can generate a database of splice junctions based on
463 the gene model annotation file and thus a better mapping result than other non-splice mapping
464 tools.

465

466 **Quantification of gene expression level**

467 featureCounts⁸² v1.5.0-p3 was used to count the reads numbers mapped to each gene. Gene
468 expression was then converted to Fragments Per Kilobase of transcript sequence per Millions
469 base pairs sequenced (FPKM), which takes the effects into consideration of both sequencing
470 depth and gene length on counting of fragments. Analysis was performed by Novogene.

471

472 **Differential expression analysis**

473 Differential expression⁸³ analysis of two conditions (three biological replicates per condition) was
474 performed using the DESeq2Rpackage⁸⁴ (1.20.0) on raw gene expression values by Novogene.
475 DESeq2 provides statistical routines for determining differential expression in digital gene
476 expression data using a model based on the negative binomial distribution. Differentially
477 expressed genes were identified by comparing 3m NP vs. 18m NP and 18m P vs 18m NP for
478 both luminal and basal cell samples. The resulting P-values were adjusted using the Benjamini-
479 Hochberg's approach for controlling the false discovery rate. Genes with an adj-p<=0.1 found by
480 DESeq2 were assigned as differentially expressed. Principal Component Analysis (PCA) plots
481 and heatmaps of differentially expressed genes were generated using the NovoMagic analysis
482 platform provided by Novogene. PCA plots are based on FPKM normalized gene expression
483 values. Heatmaps of differentially expressed genes display $\log_2(\text{FC}+1)$ values. Representative
484 genes from the top 30 DEGs are shown. See Data tables 1-4 for complete gene list.

485

486 **Enrichment analysis of differentially expressed genes**

487 Gene Ontology⁸⁵ (GO) enrichment analysis of differentially expressed genes was implemented by
488 the cluster Profiler R package, in which gene length bias was corrected. GO terms with corrected
489 p-value less than 0.1 were considered significantly enriched by differential expressed genes.

490

491 **Statistical analysis**

492 All graphs display the average as central values, and error bars indicate \pm SD unless otherwise
493 indicated. P values are calculated using paired or unpaired t test, ANOVA, Wilcoxon rank-sum
494 test, and Mann-Whitney U test, as indicated in the figure legends. All P and Q values were
495 calculated using Prism (10.2.2) or Python, unless otherwise stated. For animal studies, sample
496 size was not predetermined to ensure adequate power to detect a prespecified effect size, no
497 animals were excluded from analyses, experiments were not randomized, and investigators were
498 not blinded to group allocation during experiments.

499

500 **DATA AVAILABILITY**

501 Data generated or analyzed during this study are included in this published article (and its
502 supplemental information files). Data needed to evaluate the conclusions in the paper are present
503 in the paper and/or the Supplemental Materials. Source data files will be made available upon
504 request. Single-cell and bulk RNA-sequencing data generated in this study have been deposited
505 in the Gene Expression Omnibus with the primary accession code GSE272933 (bulk) and
506 GSE272932 (single-cell). All bioinformatics tools used in this study are published and publicly
507 available.

508

509

510

511

512

513

514

515

516

517 **References:**

- 518 1. SEER*Explorer Application [Internet]. [cited 2023 Apr 15]. Available from:
519 [https://seer.cancer.gov/statistics-](https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0)
520 [network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&ch](https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0)
521 [k_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_pr](https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0)
522 [ecision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#res](https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0)
523 [ultsRegion0](https://seer.cancer.gov/statistics-network/explorer/application.html?site=1&data_type=1&graph_type=2&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0)
- 524 2. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG,
525 Yuasa S. Age at first birth and breast cancer risk. *Bull World Health Organ.* 1970;43(2):209–
526 221. PMID: PMC2427645
- 527 3. Albrektsen G, Heuch I, Tretli S, Kvåle G. Breast cancer incidence before age 55 in relation
528 to parity and age at first and last births: a prospective study of one million Norwegian
529 women. *Epidemiology.* 1994 Nov;5(6):604–611. PMID: 7841242
- 530 4. Albrektsen G, Heuch I, Hansen S, Kvåle G. Breast cancer risk by age at birth, time since
531 birth and time intervals between births: exploring interaction effects. *Br J Cancer. Nature*
532 *Publishing Group;* 2005 Jan;92(1):167–175.
- 533 5. Russo J, Tay LK, Ciocca DR, Russo IH. Molecular and cellular basis of the mammary gland
534 susceptibility to carcinogenesis. *Environ Health Perspect.* 1983 Mar;49:185–199. PMID:
535 PMC1569117
- 536 6. Russo J, Moral R, Balogh GA, Mailo D, Russo IH. The protective role of pregnancy in breast
537 cancer. *Breast Cancer Res.* 2005;7(3):131–142. PMID: PMC1143568
- 538 7. Medina D. Breast Cancer: The Protective Effect of Pregnancy. *Clinical Cancer Research.*
539 2004 Jan 1;10(1):380s–384s.
- 540 8. Russo J, Balogh GA, Heulings R, Mailo DA, Moral R, Russo PA, Sheriff F, Vanegas J,
541 Russo IH. Molecular basis of pregnancy-induced breast cancer protection. *European*
542 *Journal of Cancer Prevention.* 2006 Aug;15(4):306.
- 543 9. Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li Y. Evidence That an Early
544 Pregnancy Causes a Persistent Decrease in the Number of Functional Mammary Epithelial
545 Stem Cells—Implications for Pregnancy-Induced Protection Against Breast Cancer. *Stem*
546 *Cells.* 2008 Dec 1;26(12):3205–3209.
- 547 10. Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ,
548 Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK,
549 Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ,
550 Argani P, Ethington G, Panos L, Grant M, Clark J, Herlihy W, Lin SJ, Chew G, Thompson
551 EW, Greene-Colozzi A, Richardson AL, Rosson GD, Pike M, Garber JE, Nikolsky Y, Blum
552 JL, Au A, Hwang ES, Tamimi RM, Michor F, Haviv I, Liu XS, Sukumar S, Polyak K.
553 Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell
554 Population with Progenitor Characteristics. *Cell Stem Cell.* 2013 Jul 3;13(1):117–130.
- 555 11. Santucci-Pereira J, Zeleniuch-Jacquotte A, Afanasyeva Y, Zhong H, Slifker M, Peri S, Ross
556 EA, López de Cicco R, Zhai Y, Nguyen T, Sheriff F, Russo IH, Su Y, Arslan AA, Bordas P,

- 557 Lenner P, Åhman J, Landström Eriksson AS, Johansson R, Hallmans G, Toniolo P, Russo
558 J. Genomic signature of parity in the breast of premenopausal women. *Breast Cancer*
559 *Research*. 2019 Mar 28;21(1):46.
- 560 12. Shalabi SF, Miyano M, Sayaman RW, Lopez JC, Jokela TA, Todhunter ME, Hinz S, Garbe
561 JC, Stampfer MR, Kessenbrock K, Seewaldt VE, LaBarge MA. Evidence for accelerated
562 aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations. *Nat*
563 *Aging*. Nature Publishing Group; 2021 Sep;1(9):838–849.
- 564 13. Pelissier Vatter FA, Schapiro D, Chang H, Borowsky AD, Lee JK, Parvin B, Stampfer MR,
565 LaBarge MA, Bodenmiller B, Lorens JB. High-Dimensional Phenotyping Identifies Age-
566 Emergent Cells in Human Mammary Epithelia. *Cell Reports*. 2018 Apr 24;23(4):1205–1219.
- 567 14. Garbe JC, Pepin F, Pelissier FA, Sputova K, Fridriksdottir AJ, Guo DE, Villadsen R, Park M,
568 Petersen OW, Borowsky AD, Stampfer MR, LaBarge MA. Accumulation of Multipotent
569 Progenitors with a Basal Differentiation Bias during Aging of Human Mammary Epithelia.
570 *Cancer Research*. 2012 Jul 15;72(14):3687–3701.
- 571 15. Pelissier FA, Garbe JC, Ananthanarayanan B, Miyano M, Lin C, Jokela T, Kumar S,
572 Stampfer MR, Lorens JB, LaBarge MA. Age-Related Dysfunction in Mechanotransduction
573 Impairs Differentiation of Human Mammary Epithelial Progenitors. *Cell Reports*. Elsevier;
574 2014 Jun 26;7(6):1926–1939. PMID: 24910432
- 575 16. Lambe M, Hsieh C cheng, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient
576 Increase in the Risk of Breast Cancer after Giving Birth. *New England Journal of Medicine*.
577 *Massachusetts Medical Society*; 1994 Jul 7;331(1):5–9.
- 578 17. Husby A, Wohlfahrt J, Øyen N, Melbye M. Pregnancy duration and breast cancer risk. *Nat*
579 *Commun*. Nature Publishing Group; 2018 Oct 23;9(1):4255.
- 580 18. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA: A Cancer Journal for*
581 *Clinicians*. 2022;72(1):7–33.
- 582 19. Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for
583 2021. *Natl Vital Stat Rep*. 2023 Jan;72(1):1–53. PMID: 36723449
- 584 20. Mathews TJ. Mean Age of Mothers is on the Rise: United States, 2000–2014. 2016;(232).
- 585 21. Reed AD, Pensa S, Steif A, Stenning J, Kunz DJ, Porter LJ, Hua K, He P, Twigger AJ, Siu
586 AJQ, Kania K, Barrow-McGee R, Goulding I, Gomm JJ, Speirs V, Jones JL, Marioni JC,
587 Khaled WT. A single-cell atlas enables mapping of homeostatic cellular shifts in the adult
588 human breast. *Nat Genet*. Nature Publishing Group; 2024 Apr;56(4):652–662.
- 589 22. Fu NY, Nolan E, Lindeman GJ, Visvader JE. Stem Cells and the Differentiation Hierarchy in
590 Mammary Gland Development. *Physiological Reviews*. American Physiological Society;
591 2020 Apr;100(2):489–523.
- 592 23. Li CMC, Shapiro H, Tsiobikas C, Selfors LM, Chen H, Rosenbluth J, Moore K, Gupta KP,
593 Gray GK, Oren Y, Steinbaugh MJ, Guerriero JL, Pinello L, Regev A, Brugge JS. Aging-
594 Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA
595 Sequencing. *Cell Reports*. 2020 Dec 29;33(13):108566.

- 596 24. Dong Q, Gao H, Shi Y, Zhang F, Gu X, Wu A, Wang D, Chen Y, Bandyopadhyay A, Yeh IT,
597 Daniel BJ, Chen Y, Zou Y, Rebel VL, Walter CA, Lu J, Huang C, Sun LZ. Aging is
598 associated with an expansion of CD49^{hi} mammary stem cells that show a decline in
599 function and increased transformation potential. *Aging*. 2016 Nov 15;8(11):2754–2776.
600 PMID: 27852980
- 601 25. Bach K, Pensa S, Grzelak M, Hadfield J, Adams DJ, Marioni JC, Khaled WT. Differentiation
602 dynamics of mammary epithelial cells revealed by single-cell RNA sequencing. *Nat*
603 *Commun*. Nature Publishing Group; 2017 Dec 11;8(1):2128.
- 604 26. Pal B, Chen Y, Vaillant F, Jamieson P, Gordon L, Rios AC, Wilcox S, Fu N, Liu KH, Jackling
605 FC, Davis MJ, Lindeman GJ, Smyth GK, Visvader JE. Construction of developmental
606 lineage relationships in the mouse mammary gland by single-cell RNA profiling. *Nat*
607 *Commun*. Nature Publishing Group; 2017 Nov 20;8(1):1627.
- 608 27. Walker MR, Amante JJ, Li J, Liu H, Zhu LJ, Feltri ML, Goel HL, Mercurio AM. Alveolar
609 progenitor cells in the mammary gland are dependent on the $\beta 4$ integrin. *Developmental*
610 *Biology*. 2020 Jan 1;457(1):13–19.
- 611 28. Fu NY, Rios AC, Pal B, Law CW, Jamieson P, Liu R, Vaillant F, Jackling F, Liu KH, Smyth
612 GK, Lindeman GJ, Ritchie ME, Visvader JE. Identification of quiescent and spatially
613 restricted mammary stem cells that are hormone responsive. *Nat Cell Biol*. Nature
614 Publishing Group; 2017 Mar;19(3):164–176.
- 615 29. Cai S, Kalisky T, Sahoo D, Dalerba P, Feng W, Lin Y, Qian D, Kong A, Yu J, Wang F, Chen
616 EY, Scheeren FA, Kuo AH, Sikandar SS, Hisamori S, Weele LJ van, Heiser D, Sim S, Lam
617 J, Quake S, Clarke MF. A Quiescent Bcl11b High Stem Cell Population Is Required for
618 Maintenance of the Mammary Gland. *Cell Stem Cell*. Elsevier; 2017 Feb 2;20(2):247-
619 260.e5. PMID: 28041896
- 620 30. Dallas DC, Murray NM, Gan J. Proteolytic Systems in Milk: Perspectives on the Evolutionary
621 Function within the Mammary Gland and the Infant. *J Mammary Gland Biol Neoplasia*. 2015
622 Dec;20(0):133–147. PMCID: PMC4637187
- 623 31. Hassiotou F, Geddes DT. Immune Cell–Mediated Protection of the Mammary Gland and the
624 Infant during Breastfeeding. *Advances in Nutrition*. 2015 May 1;6(3):267–275.
- 625 32. Goldman AS, Chheda S, Garofalo R. Evolution of Immunologic Functions of the Mammary
626 Gland and the Postnatal Development of Immunity. *Pediatr Res*. Nature Publishing Group;
627 1998 Feb;43(2):155–162.
- 628 33. Bai H, Liu X, Lin M, Meng Y, Tang R, Guo Y, Li N, Clarke MF, Cai S. Progressive
629 senescence programs induce intrinsic vulnerability to aging-related female breast cancer.
630 *Nat Commun*. Nature Publishing Group; 2024 Jun 17;15(1):5154.
- 631 34. Almanzar N, Antony J, Baghel AS, Bakerman I, Bansal I, Barres BA, Beachy PA, Berdnik D,
632 Bilen B, Brownfield D, Cain C, Chan CKF, Chen MB, Clarke MF, Conley SD, Darmanis S,
633 Demers A, Demir K, de Morree A, Divita T, du Bois H, Ebadi H, Espinoza FH, Fish M, Gan
634 Q, George BM, Gillich A, Gómez-Sjöberg R, Green F, Genetiano G, Gu X, Gulati GS, Hahn
635 O, Haney MS, Hang Y, Harris L, He M, Hosseinzadeh S, Huang A, Huang KC, Iram T, Isobe
636 T, Ives F, Jones RC, Kao KS, Karkanias J, Karnam G, Keller A, Kershner AM, Khoury N,

- 637 Kim SK, Kiss BM, Kong W, Krasnow MA, Kumar ME, Kuo CS, Lam J, Lee DP, Lee SE,
638 Lehallier B, Leventhal O, Li G, Li Q, Liu L, Lo A, Lu WJ, Lugo-Fagundo MF, Manjunath A,
639 May AP, Maynard A, McGeever A, McKay M, McNERney MW, Merrill B, Metzger RJ,
640 Mignardi M, Min D, Nabhan AN, Neff NF, Ng KM, Nguyen PK, Noh J, Nusse R, Pálovics R,
641 Patkar R, Peng WC, Penland L, Pisco AO, Pollard K, Puccinelli R, Qi Z, Quake SR, Rando
642 TA, Rulifson EJ, Schaum N, Segal JM, Sikandar SS, Sinha R, Sit RV, Sonnenburg J,
643 Staehli D, Szade K, Tan M, Tan W, Tato C, Tellez K, Dulgeroff LBT, Travaglini KJ, Tropini
644 C, Tsui M, Waldburger L, Wang BM, van Weele LJ, Weinberg K, Weissman IL, Wosczyzna
645 MN, Wu SM, Wyss-Coray T, Xiang J, Xue S, Yamauchi KA, Yang AC, Yerra LP,
646 Youngyunpipatkul J, Yu B, Zanini F, Zardeneta ME, Zee A, Zhao C, Zhang F, Zhang H,
647 Zhang MJ, Zhou L, Zou J, The Tabula Muris Consortium. A single-cell transcriptomic atlas
648 characterizes ageing tissues in the mouse. *Nature*. Nature Publishing Group; 2020
649 Jul;583(7817):590–595.
- 650 35. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M, Smalley MJ.
651 Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants
652 of lineage commitment and cell fate. *BMC Genomics*. 2008 Dec 8;9(1):591.
- 653 36. Wolf FA, Hamey FK, Plass M, Solana J, Dahlin JS, Göttgens B, Rajewsky N, Simon L,
654 Theis FJ. PAGA: graph abstraction reconciles clustering with trajectory inference through a
655 topology preserving map of single cells. *Genome Biology*. 2019 Mar 19;20(1):59.
- 656 37. Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N, Purdom E, Dudoit S. Slingshot: cell
657 lineage and pseudotime inference for single-cell transcriptomics. *BMC Genomics*. 2018 Jun
658 19;19(1):477.
- 659 38. Kang M, Armenteros JJA, Gulati GS, Gleyzer R, Avagyan S, Brown EL, Zhang W, Usmani
660 A, Earland N, Wu Z, Zou J, Fields RC, Chen DY, Chaudhuri AA, Newman AM. Mapping
661 single-cell developmental potential in health and disease with interpretable deep learning
662 [Internet]. *bioRxiv*; 2024 [cited 2024 Jul 12]. p. 2024.03.19.585637. Available from:
663 <https://www.biorxiv.org/content/10.1101/2024.03.19.585637v1>
- 664 39. Bu W, Chen J, Morrison GD, Huang S, Creighton CJ, Huang J, Chamness GC, Hilsenbeck
665 SG, Roop DR, Leavitt AD, Li Y. Keratin 6a marks mammary bipotential progenitor cells that
666 can give rise to a unique tumor model resembling human normal-like breast cancer.
667 *Oncogene*. Nature Publishing Group; 2011 Oct;30(43):4399–4409.
- 668 40. Smith GH, Mehrel T, Roop DR. Differential keratin gene expression in developing,
669 differentiating, preneoplastic, and neoplastic mouse mammary epithelium. *Cell Growth*
670 *Differ*. 1990 Apr;1(4):161–170. PMID: 1707299
- 671 41. Pal B, Chen Y, Milevskiy MJG, Vaillant F, Prokopuk L, Dawson CA, Capaldo BD, Song X,
672 Jackling F, Timpson P, Lindeman GJ, Smyth GK, Visvader JE. Single cell transcriptome
673 atlas of mouse mammary epithelial cells across development. *Breast Cancer Res*. 2021 Jun
674 29;23(1):69. PMID: PMC8243869
- 675 42. Kim JY, Kim G, Lim SC, Choi HS. IL-33-Induced Transcriptional Activation of LPIN1
676 Accelerates Breast Tumorigenesis. *Cancers*. Multidisciplinary Digital Publishing Institute;
677 2021 Jan;13(9):2174.

- 678 43. Kim JY, Lim SC, Kim G, Yun HJ, Ahn SG, Choi HS. Interleukin-33/ST2 axis promotes
679 epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
680 *Oncogene*. Nature Publishing Group; 2015 Sep;34(38):4928–4938.
- 681 44. Liu J, Shen JX, Hu JL, Huang WH, Zhang GJ. Significance of Interleukin-33 and Its Related
682 Cytokines in Patients with Breast Cancers. *Frontiers in Immunology* [Internet]. 2014 [cited
683 2023 Apr 16];5. Available from:
684 <https://www.frontiersin.org/articles/10.3389/fimmu.2014.00141>
- 685 45. Hu H, Sun J, Wang C, Bu X, Liu X, Mao Y, Wang H. IL-33 facilitates endocrine resistance of
686 breast cancer by inducing cancer stem cell properties. *Biochem Biophys Res Commun*.
687 2017 Apr 8;485(3):643–650. PMID: 28216163
- 688 46. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN,
689 Lukic ML. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by
690 facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. *Int J*
691 *Cancer*. 2014 Apr 1;134(7):1669–1682. PMID: 24105680
- 692 47. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks
693 T. Cre-lox-regulated conditional RNA interference from transgenes. *Proceedings of the*
694 *National Academy of Sciences*. *Proceedings of the National Academy of Sciences*; 2004 Jul
695 13;101(28):10380–10385.
- 696 48. Jena MK, Jaswal S, Kumar S, Mohanty AK. Molecular mechanism of mammary gland
697 involution: An update. *Developmental Biology*. 2019 Jan 15;445(2):145–155.
- 698 49. Watson CJ, Kreuzaler PA. Remodeling mechanisms of the mammary gland during
699 involution. *The International Journal of Developmental Biology*. UPV/EHU Press; 2011 Nov
700 29;55(7–8–9):757–762.
- 701 50. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, Bell AK, Ferrier RK,
702 Sandilands GP, Gusterson BA. Involution of the mouse mammary gland is associated with
703 an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3.
704 *Breast Cancer Research*. 2003 Dec 18;6(2):R75.
- 705 51. Stein T, Salomonis N, Gusterson BA. Mammary Gland Involution as a Multi-step Process. *J*
706 *Mammary Gland Biol Neoplasia*. 2007 Mar 1;12(1):25–35.
- 707 52. Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A,
708 Bergholtz H, Ghamrasni SE, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lü Y, Oh RH, Kozma KJ,
709 Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader
710 GD, Egan SE, Cescon DW, Sørlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK,
711 Knudsen ES, Pujana MA, Wahl GM, Schramek D. Loss of Epigenetic Regulation Disrupts
712 Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. *Cancer*
713 *Discov*. 2022 Dec 2;12(12):2930–2953. PMID: 3612400
- 714 53. Christin JR, Wang C, Chung CY, Liu Y, Dravis C, Tang W, Oktay MH, Wahl GM, Guo W.
715 Stem Cell Determinant SOX9 Promotes Lineage Plasticity and Progression in Basal-like
716 Breast Cancer. *Cell Reports*. 2020 Jun 9;31(10):107742.

- 717 54. Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, Wuidart A,
718 Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C. Reactivation of
719 multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. *Nature*. 2015 Sep
720 3;525(7567):119–123. PMID: 26266985
- 721 55. Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T,
722 Kohler H, Aina O, Cardiff RD, Bentires-Alj M. PIK3CAH1047R induces multipotency and
723 multi-lineage mammary tumours. *Nature*. Nature Publishing Group; 2015
724 Sep;525(7567):114–118.
- 725 56. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, MacKay A,
726 Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ. *BRCA1* Basal-like Breast
727 Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells. *Cell*
728 *Stem Cell*. 2010 Sep 3;7(3):403–417.
- 729 57. Lloyd-Lewis B, Gobbo F, Perkins M, Jacquemin G, Huyghe M, Faraldo MM, Fre S. In vivo
730 imaging of mammary epithelial cell dynamics in response to lineage-biased Wnt/ β -catenin
731 activation. *Cell Rep*. 2022 Mar 8;38(10):110461. PMID: PMC7615182
- 732 58. Oprean CM, Negru SM, Popovici DI, Saftescu S, Han RA, Dragomir GM, Hoinoiu T, Dema
733 A. Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related
734 to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years.
735 Follow-Up Data. *Int J Environ Res Public Health*. 2020 Dec;17(23):8722. PMID:
736 PMC7727650
- 737 59. Davis FM, Lloyd-Lewis B, Harris OB, Kozar S, Winton DJ, Muresan L, Watson CJ. Single-
738 cell lineage tracing in the mammary gland reveals stochastic clonal dispersion of
739 stem/progenitor cell progeny. *Nat Commun*. Nature Publishing Group; 2016 Oct
740 25;7(1):13053.
- 741 60. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, Sharma N,
742 Dekoninck S, Blanpain C. Distinct stem cells contribute to mammary gland development and
743 maintenance. *Nature*. 2011 Nov;479(7372):189–193.
- 744 61. Rios AC, Fu NY, Lindeman GJ, Visvader JE. In situ identification of bipotent stem cells in
745 the mammary gland. *Nature*. Nature Publishing Group; 2014 Feb;506(7488):322–327.
- 746 62. van Amerongen R, Bowman AN, Nusse R. Developmental Stage and Time Dictate the Fate
747 of Wnt/ β -Catenin-Responsive Stem Cells in the Mammary Gland. *Cell Stem Cell*. Elsevier;
748 2012 Sep 7;11(3):387–400. PMID: 22863533
- 749 63. Cayrol C, Girard JP. Interleukin-33 (IL-33): A critical review of its biology and the
750 mechanisms involved in its release as a potent extracellular cytokine. *Cytokine*. 2022 Aug
751 1;156:155891.
- 752 64. Alonso-Curbelo D, Ho YJ, Burdziak C, Maag JLV, Morris JP, Chandwani R, Chen HA,
753 Tsanov KM, Barriga FM, Luan W, Tasdemir N, Livshits G, Azizi E, Chun J, Wilkinson JE,
754 Mazutis L, Leach SD, Koche R, Pe'er D, Lowe SW. A gene–environment-induced epigenetic
755 program initiates tumorigenesis. *Nature*. Nature Publishing Group; 2021
756 Feb;590(7847):642–648.

- 757 65. Stier MT, Mitra R, Nyhoff LE, Goleniewska K, Zhang J, Puccetti MV, Casanova HC,
758 Seegmiller AC, Newcomb DC, Kendall PL, Eischen CM, Peebles RS Jr. IL-33 Is a Cell-
759 Intrinsic Regulator of Fitness during Early B Cell Development. *The Journal of Immunology*.
760 2019 Sep 15;203(6):1457–1467.
- 761 66. Yin H, Li X, Hu S, Liu T, Yuan B, Gu H, Ni Q, Zhang X, Zheng F. IL-33 accelerates
762 cutaneous wound healing involved in upregulation of alternatively activated macrophages.
763 *Mol Immunol*. 2013 Dec;56(4):347–353. PMID: 23911389
- 764 67. Kurimoto M, Watanabe T, Kamata K, Minaga K, Kudo M. IL-33 as a Critical Cytokine for
765 Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis. *Front Physiol*
766 [Internet]. *Frontiers*; 2021 Oct 25 [cited 2024 Jul 17];12. Available from:
767 <https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.781012/full>
- 768 68. Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, Lobo NA, Scheeren FA, Sim
769 S, Qian D, Dirbas FM, Somlo G, Quake SR, Clarke MF. Role of epithelial to mesenchymal
770 transition associated genes in mammary gland regeneration and breast tumorigenesis. *Nat*
771 *Commun*. Nature Publishing Group; 2017 Nov 21;8(1):1669.
- 772 69. Zabala M, Lobo NA, Antony J, Heitink LS, Gulati GS, Lam J, Parashurama N, Sanchez K,
773 Adorno M, Sikandar SS, Kuo AH, Qian D, Kalisky T, Sim S, Li L, Dirbas FM, Somlo G,
774 Newman A, Quake SR, Clarke MF. LEFTY1 Is a Dual-SMAD Inhibitor that Promotes
775 Mammary Progenitor Growth and Tumorigenesis. *Cell Stem Cell*. 2020 Aug 6;27(2):284-
776 299.e8.
- 777 70. Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, Haro-Acosta V, Das S, Steen
778 CB, Pereira TA, Qian D, Beachy PA, Dirbas FM, Red-Horse K, Rabbitts TH, Thiery JP,
779 Newman AM, Clarke MF. Identification of a minority population of LMO2+ breast cancer
780 cells that integrate into the vasculature and initiate metastasis. *Science Advances*. American
781 Association for the Advancement of Science; 2022 Nov 9;8(45):eabm3548.
- 782 71. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data
783 analysis. *Genome Biology*. 2018 Feb 6;19(1):15.
- 784 72. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M,
785 Loh P ru, Raychaudhuri S. Fast, sensitive and accurate integration of single-cell data with
786 Harmony. *Nat Methods*. Nature Publishing Group; 2019 Dec;16(12):1289–1296.
- 787 73. Traag VA, Waltman L, van Eck NJ. From Louvain to Leiden: guaranteeing well-connected
788 communities. *Sci Rep*. Nature Publishing Group; 2019 Mar 26;9(1):5233.
- 789 74. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for
790 Dimension Reduction [Internet]. arXiv; 2020 [cited 2024 Jul 17]. Available from:
791 <http://arxiv.org/abs/1802.03426>
- 792 75. `scanpy_usage/180209_cell_cycle/data/regev_lab_cell_cycle_genes.txt` at master ·
793 `scverse/scanpy_usage` [Internet]. GitHub. [cited 2024 Jul 17]. Available from:
794 [https://github.com/scverse/scanpy_usage/blob/master/180209_cell_cycle/data/regev_lab_c](https://github.com/scverse/scanpy_usage/blob/master/180209_cell_cycle/data/regev_lab_cell_cycle_genes.txt)
795 `ell_cycle_genes.txt`

- 796 76. Waskom ML. seaborn: statistical data visualization. *Journal of Open Source Software*. 2021
797 Apr 6;6(60):3021.
- 798 77. Hunter JD. Matplotlib: A 2D Graphics Environment. *Computing in Science & Engineering*.
799 2007 May;9(3):90–95.
- 800 78. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E,
801 Peterson P, Weckesser W, Bright J, van der Walt SJ, Brett M, Wilson J, Millman KJ,
802 Mayorov N, Nelson ARJ, Jones E, Kern R, Larson E, Carey CJ, Polat I, Feng Y, Moore EW,
803 VanderPlas J, Laxalde D, Perktold J, Cimrman R, Henriksen I, Quintero EA, Harris CR,
804 Archibald AM, Ribeiro AH, Pedregosa F, van Mulbregt P. SciPy 1.0: fundamental algorithms
805 for scientific computing in Python. *Nat Methods*. Nature Publishing Group; 2020
806 Mar;17(3):261–272.
- 807 79. Josef Perktold, Skipper Seabold, Kevin Sheppard, ChadFulton, Kerby Shedden,
808 jbrockmendel, j-grana6, Peter Quackenbush, Vincent Arel-Bundock, Wes McKinney, Ian
809 Langmore, Bart Baker, Ralf Gommers, yogabonito, s-scherrer, Yauhen Zhurko, Matthew
810 Brett, Enrico Giampieri, yl565, Jarrod Millman, Paul Hobson, Vincent, Pamphile Roy, Tom
811 Augspurger, tvanzyl, alexbr, Tyler Hartley, Fernando Perez, Yuji Tamiya, Yaroslav
812 Halchenko. statsmodels/statsmodels: Release 0.14.2 [Internet]. Zenodo; 2024 [cited 2024
813 Jul 23]. Available from: <https://zenodo.org/doi/10.5281/zenodo.593847>
- 814 80. Parkhomchuk D, Borodina T, Amstislavskiy V, Banaru M, Hallen L, Krobitch S, Lehrach H,
815 Soldatov A. Transcriptome analysis by strand-specific sequencing of complementary DNA.
816 *Nucleic Acids Research*. 2009 Oct 1;37(18):e123.
- 817 81. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying
818 mammalian transcriptomes by RNA-Seq. *Nat Methods*. Nature Publishing Group; 2008
819 Jul;5(7):621–628.
- 820 82. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for
821 assigning sequence reads to genomic features. *Bioinformatics*. 2014 Apr 1;30(7):923–930.
- 822 83. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome*
823 *Biology*. 2010 Oct 27;11(10):R106.
- 824 84. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
825 seq data with DESeq2. *Genome Biology*. 2014 Dec 5;15(12):550.
- 826 85. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq:
827 accounting for selection bias. *Genome Biology*. 2010 Feb 4;11(2):R14.

828

829

830

831

832 **ACKNOWLEDGMENTS**

833 We thank Bari Nazario for her help in flow cytometry. The FACS Aria instrument was funded by
834 NIH grant S10-1S10RR02933801. We thank Benjamin Abrams, UCSC Life Sciences Microscopy
835 Center, RRID: SCR_021135 for technical support during image acquisition and processing. We
836 also thank the animal facility core members for animal maintenance. We thank Camilla Forsberg,
837 Lindsay Hinck, Aaron Newman and members of the Sikandar lab for critical feedback on the
838 manuscript. The authors declare no competing interests. This work was supported by the Hellman
839 Fellows Award and startup funds (to S.S.S), NIH T-32 (5T32GM133391-04) (to A.O), the Eugene
840 Cota-Robles Fellowship (to C.M.R) and startup funds (to V.D.J). S.S.S is also supported by the
841 NIH/NCI (R37CA269754).

842

843 **AUTHOR CONTRIBUTIONS**

844 S.S.S. and A.O conceived and designed the study. A.O performed most of the experiments and
845 analyzed the data with assistance from V.H.A and S.K and under the supervision of S.S.S. V.H.A
846 collected samples for single-cell RNA sequencing and processed samples for bulk-RNA
847 sequencing. P.M verified the differential gene expression analysis from bulk RNA sequencing
848 data. C.M.R analyzed single-cell RNA sequencing data under supervision of V.D.J. A.O and
849 S.S.S. wrote the manuscript with contributions from C.M.R and V.D.J. All authors commented on
850 the manuscript.

851

852 **COMPETING INTERESTING**

853 The authors declare no competing interests.


854

855 **EXTENDED DATA:**

856 Extended data figures 1-6

857 Tables 1-5

858 **MAIN FIGURES AND LEGENDS**



859

860 **Figure 1. Pregnancy induces persistent changes in cell fate decisions and reduces**

861 **organoid formation.** (a) Schematic of flow cytometry analysis for 3-month nulliparous (3m NP),

862 18-month nulliparous (18m NP), and 18-month parous (18m P). Created with Biorender.com. (b)

863 Representative flow cytometry plots of DAPI-/CD45-/CD31-/Ter119- single cells from mouse

864 mammary tissues. Basal (EPCAM^{med/low}CD49f^{high}) and luminal (EPCAM^{high}CD49f^{med/low}) cells are

865 denoted by representative gates. (c) Quantification of flow cytometry data shown in (b) (n = 11
866 mice). (d) Representative flow cytometry plots of DAPI-/Lineage-/EPCAM^{high}CD49f^{med/low} single
867 cells from mouse mammary tissues. (e) Quantification of flow cytometry data shown in (d) (n = 4
868 mice). (f) Representative images of primary organoids derived from 3m NP, 18m NP, and 18m
869 P luminal cells. (g) Quantification of luminal organoid number. (h) Quantification of basal
870 organoid number. (i) Representative images of primary organoids derived from 3m NP, 18m NP,
871 and 18m P basal cells. n = 8 mice for experiments in f-i. Statistical significance was determined
872 by performing ANOVA (d, e) or paired t tests (g, i). * p < 0.05, ** p < 0.01, *** p < 0.001.

873

874

875

876

877

878

879

880

881

882

883

884

885


886

887

888

889

890



891

892 **Figure 2. Bulk RNA sequencing in aged nulliparous and parous mammary glands reveals**

893 **long-lasting transcriptomic changes.** (a) Principal Component Analysis (PCA) of basal and

894 luminal RNA-seq samples from 3m NP, 18m NP, and 18m P mice. (b) Bar plot depicting the

895 expression (FPKM $\times 10^3$) of basal (*Krt14*, *Krt15*, *Acta2*) and luminal (*Krt18*, *Krt8*) marker genes
896 across samples. (c) Heatmap of differentially expressed genes (DEGs) across 3m NP, 18m NP,
897 and 18m P basal cells and (d) luminal cells. Relative expression reflects $\log_2(\text{FC}+1)$ values.
898 Significance was determined using an adj-p value of ≤ 0.1 . (e, f) Dotplot of Gene Ontology
899 (GO) results for 18m P basal (e) and luminal (f) cells, relative to 18m NP. GO results were
900 selected from the top 15 hits with the lowest adj-p value denoted as q-value (< 0.03 for basal, $<$
901 0.08 for luminal), NES = Normalized Enrichment Score. Gene number refers to the number of
902 genes from the input gene list that are present in the GO gene list.

903

904

905

906

907

908

909

910

911

912

913

914

915


916

917

918

919

920



921
 922 **Figure 3. Single cell RNA sequencing identifies a hybrid population of MECs in aged**
 923 **nulliparous mice but is reduced in aged parous mice.** (a) UMAP plot of scRNA-seq data
 924 generated from the mammary glands of 18m nulliparous (NP, red) and parous (P, blue) mice (n
 925 = 3 mice) and integrated with Tabula Muris (n=10,001). UMAPs are colored by condition (left)

926 and annotated cell type (right). (b) Bar plot showing the proportion of cell types by condition. (c)
927 Dotplot of gene expression for selected marker genes of mammary cell lineages. (d) Basal, HR-
928 low, and HR-high gene expression scores across epithelial clusters (black), including a minority
929 population of hybrid MECs (pink). (e) Violin plot showing the distribution of inferred partition-
930 based graph abstraction (PAGA) pseudotime scores across epithelial cell clusters. (f) Violin plot
931 comparing predicted developmental potential (obtained through CytoTRACE 2) across epithelial
932 cell clusters. (g) Representative immunofluorescence (IF) stains against KRT5 (basal cells,
933 green), KRT6a (hybrid MECs, red), and KRT8 (luminal cells, magenta). Nuclei are visualized
934 using DAPI (blue). Hybrid MECs localized to the basal layer are indicated by white arrows. (h)
935 Quantification of all KRT6a+ hybrid MECs in the epithelium. (i) Quantification of the localization
936 of KRT6a+ hybrid MECs (basal or luminal). Statistical significance was determined by
937 performing one-way ANOVA with Tukey test (d) or unpaired t tests with Welch's correction to
938 account for unequal standard deviations (h). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Statistical tests
939 for scRNA-sequencing are described in the methods section. $n = 5$ mice for IF experiments.
940 Scale bar = 50 μm .

941

942

943

944


945

946

947

948

949



950

951 **Figure 4. IL33 treatment of young basal cells phenocopies aged nulliparous MECs. (a)**

952 Representative images of primary basal organoids from 3m NP mice treated with no IL33

953 treatment (top left) and with IL33 treatment (bottom left). Quantification of the number of

954 organoids formed with 0, 5, or 10ng/mL of IL33. (b) Representative flow cytometry plots of basal

955 and luminal cells from IL33-treated organoids (left) and the quantified proportion of basal cells

956 relative to the luminal population (right). (c) Representative IF stains (left) against KRT5 (basal

957 cells), KRT6a (hybrid MECs), and KRT8 (luminal cells) on IL33-treated organoids. Nuclei are

958 visualized using DAPI. Quantification of KRT6a+ area in basal organoids cultured with 0, 5, or

959 10ng/mL of IL33 (right). (d) Representative images of preneoplastic (shTrp53) basal organoids

960 treated with (top left, 10ng/mL) or without IL33 (bottom left). Quantification of the number of

961 shTrp53- basal organoids formed with or without IL33 treatment after 12 days in culture (right).

962 Statistical significance was determined by performing unpaired t tests (a-c) or 2-way ANOVA

963 with Šídák's multiple comparisons test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. $n = 3$ mice. Scale
964 bar = 1000 μm (a, d) and 100 μm (c).